Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients
- PMID: 22707395
- DOI: 10.1002/hep.25889
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients
Abstract
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight is a significant risk factor. The aim was to build an algorithm along with a scoring system for histopathologic classification of liver lesions that covers the entire spectrum of lesions in morbidly obese patients. A cohort of 679 obese patients undergoing liver biopsy at the time of bariatric surgery was studied. An algorithm for segregating lesions into normal liver, NAFLD, or nonalcoholic steatohepatitis (NASH) was built based on semiquantitative evaluation of steatosis, hepatocellular ballooning, and lobular inflammation. For each case, the SAF score was created including the semiquantitative scoring of steatosis (S), activity (A), and fibrosis (F). Based on the algorithm, 230 obese patients (34%) were categorized as NASH, 291 (43%) as NAFLD without NASH, and 158 (23%) as not NAFLD. The activity score (ballooning + lobular inflammation) enabled discriminating NASH because all patients with NASH had A ≥ 2, whereas no patients with A < 2 had NASH. This score was closely correlated with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (P < 0.0001, analysis of variance [ANOVA]). Comparison of transaminase levels between patients with normal liver and pure steatosis did not reveal significant differences, thus lending support to the proposal not to include steatosis in the activity score but to report it separately in the SAF score. In the validation series, the interobserver agreement for the diagnosis of NASH was excellent (κ = 0.80) between liver pathologists. There was no discrepancy between the initial diagnosis and the diagnosis proposed using the algorithm.
Conclusion: We propose a simple but robust algorithm for categorizing liver lesions in NAFLD patients. Because liver lesions in obese patients may display a continuous spectrum of histologic lesions, we suggest describing liver lesions using the SAF score.
Copyright © 2012 American Association for the Study of Liver Diseases.
Similar articles
-
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.Obes Surg. 2005 Mar;15(3):310-5. doi: 10.1381/0960892053576820. Obes Surg. 2005. PMID: 15826462
-
Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.Obes Surg. 2006 Dec;16(12):1584-93. doi: 10.1381/096089206779319392. Obes Surg. 2006. PMID: 17217634
-
Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.Chirurgia (Bucur). 2012 Nov-Dec;107(6):772-9. Chirurgia (Bucur). 2012. PMID: 23294957
-
Non-alcoholic steatohepatitis in children.Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x. Pediatr Transplant. 2004. PMID: 15598336 Review.
-
[Role of liver biopsy in the diagnosis of NASH].Nihon Rinsho. 2006 Jun;64(6):1119-25. Nihon Rinsho. 2006. PMID: 16768119 Review. Japanese.
Cited by
-
Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations.Gastro Hep Adv. 2022 May 14;1(5):882-893. doi: 10.1016/j.gastha.2022.05.006. eCollection 2022. Gastro Hep Adv. 2022. PMID: 39131840 Free PMC article. Review.
-
Nonalcoholic Steatohepatitis: A 9-Year Follow Up Cohort Study.J Clin Med. 2022 Oct 10;11(19):5969. doi: 10.3390/jcm11195969. J Clin Med. 2022. PMID: 36233834 Free PMC article.
-
Liver biopsy-proven non-alcoholic fatty liver disease predicts no impact on antiviral response in patients with chronic hepatitis B.Clinics (Sao Paulo). 2024 Sep 26;79:100493. doi: 10.1016/j.clinsp.2024.100493. eCollection 2024. Clinics (Sao Paulo). 2024. PMID: 39332149 Free PMC article.
-
G-Protein-Coupled Receptor 120 Agonist Mitigates Steatotic and Fibrotic Features Triggered in Obese Mice by the Administration of a High-Fat and High-Carbohydrate Diet.ACS Omega. 2024 Jul 10;9(29):31899-31909. doi: 10.1021/acsomega.4c03507. eCollection 2024 Jul 23. ACS Omega. 2024. PMID: 39072106 Free PMC article.
-
Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations.Front Nutr. 2022 Nov 16;9:1051157. doi: 10.3389/fnut.2022.1051157. eCollection 2022. Front Nutr. 2022. PMID: 36466421 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical